The chromosomal translocation (8;21) fuses the hematopoietic transcription factor AML1 (RUNX1) with ETO (RUNX1T1, MTG8), resulting in the leukemia-specific chimeric protein AML1/ETO. This fusion protein has been implicated in epigenetic silencing, recruiting histone deacetylases (HDACs) and DNA methyltransferases to target promoters. Previously, we have identified a novel in vivo AML1/ETO target gene, LAT2 (NTAL/LAB/ WBSCR5), which is involved in FceR I, c-Kit, B-cell and T-cell receptor signalling. We have now addressed the molecular mechanisms of AML1/ETO-mediated LAT2 repression. In Kasumi-1 cells, where AML1/ETO bound to the LAT2 gene, small interfering RNA (siRNA)-mediated AML1/ETO depletion caused upregulation of LAT2, suggesting a possible direct mechanism of repression. Expression of AML1/ETO was associated with a decrease in acetylation of histones H3, H3K9 and H4, and an increase in H3K9 and H3K27 trimethylation. The class I-specific HDAC inhibitors entinostat (MS-275) and mocetinostat (MGCD0103) induced LAT2 expression specifically in AML1/ETO-expressing cells, resulting in induction of several activating histone marks on the LAT2 gene, including trimethylation of histone H3K4. The combination of entinostat and decitabine increased acetylation of histones H3 and H4, as well as LAT2 mRNA expression, in an at least additive fashion. In conclusion, several repressive histone modifications mark the LAT2 gene in the presence of AML1/ETO, and LAT2 gene derepression is achieved by pharmacological inhibition of HDACs.
Introduction
One of the most common chromosomal translocations in AML (acute myeloid leukemia) is the t(8;21) fusing the N-terminal part of the hematopoietic transcription factor gene AML1 (RUNX1) on chromosome 21 to the ETO (MTG8, RUNX1T1) gene on chromosome 8 (Erickson et al., 1992) . ETO recruits a nuclear corepressor complex containing class I histone deacetylases (HDACs) 1-3 through its interaction with N-COR and SIN3A to the promoters of its target genes, acting as a transcriptional repressor by deacetylating the histones around promoters (Gelmetti et al., 1998; Lutterbach et al., 1998; Amann et al., 2001) . AML1/ETO represses interleukin-3 expression, which can be reverted by treatment with the HDAC inhibitor depsipeptide (Klisovic et al., 2003) and the DNA demethylating agent decitabine (Liu et al., 2005) . At the IL3 promoter, AML1/ETO is part of a repressive complex containing HDAC-1 and DNA methyltransferase 1 (DNMT1). This complex can be disrupted by treatment with the HDAC inhibitors valproic acid (VPA) and depsipeptide, but not with a DNMT inhibitor (Liu et al., 2005) . Recently, a complex constituted by AML1/ETO and DNMT1 was also demonstrated to be physically associated with the RARb2 promoter (Fazi et al., 2007) , linking it with histone acetylation and DNA methylation, the two major epigenetic changes so far associated with the molecular pathogenesis of AML1/ETO-positive AML.
A novel AML1/ETO target gene, localized on the long arm of chromosome 7, band q11.23, involved in the microdeletion of Williams Beuren Syndrome (Pober, 2010) , termed non-T-cell activation linker (NTAL), linker for activation of B cells (LAB) or linker for activation of T cells family, member 2 (LAT2) codes for a 28-kDa membrane protein (Brdicka et al., 2002; Janssen et al., 2003; Zhu et al., 2006) . LAT2 acts as an adaptor molecule, which is phosphorylated and activated by several membrane receptors, that is, FceR I and c-Kit receptor in mast cells (Tkaczyk et al., 2004; Volna et al., 2004; Zhu et al., 2004) , B-and T-cell receptor in B and T cells, respectively (Janssen et al., 2003; Wang et al., 2005; Zhu et al., 2006) . After its phosphorylation and activation, LAT2 regulates several signalling pathways interacting with cytoplasmic partner proteins, including GRB2 (Brdicka et al., 2002; Stork et al., 2004) and CBL (Brdicka et al., 2002) . Recently, we could show that, LAT2 inhibits the in vitro myeloid differentiation of AML1/ETO-positive cells (Duque-Afonso et al., 2011) .
LAT2 was first identified by complementary DNArepresentational difference analysis as a strongly downregulated transcript following conditional expression of AML1/ETO induced by Ponasterone A in the 9/14/18-U937 cell line, confirmed in t(8;21)-positive cell lines and primary AML blasts (Fliegauf et al., 2004) . In this study, we show that AML1/ETO-mediated repression of LAT2 is relieved in Kasumi-1 cells by knockdown of AML1/ETO with siRNAs and by treatment with two class I-specific HDAC inhibitors. Several histone modifications marking the LAT2 gene and mediated by AML1/ETO were antagonized by the class I-specific HDAC inhibitor entinostat. Thus, interference with AML1/ETO-mediated epigenetic alteration provides a therapeutic option in AML.
Results

LAT2 is a target gene of AML1/ETO
Multiple genes have been described as in vitro targets of the chimeric transcription factor AML1/ETO. However, there are only a very limited number of AML1/ETO target genes (for example, p14
arf and C/EBPa), whose regulation was validated in vivo in primary AML blasts Linggi et al., 2002) . Three groups have engineered human cell line models of inducible AML1/ETO expression (Burel et al., 2001; Alcalay et al., 2003; Fliegauf et al., 2004) . Employing a conditional AML1/ETO expression model based on an ecdysone-inducible system in myeloid U937 cells (9/14/ 18-U937 cells), we had identified LAT2 mRNA by complementary DNA-representational difference analysis as a strongly repressed transcript after 48 h of conditional expression of AML1/ETO (Fliegauf et al., 2004) . This was confirmed by western blot (data not shown) and in a large series of primary AML blasts (Duque-Afonso et al., 2011) .
We next studied the expression of LAT2 in an AML1/ ETO knockdown system (Heidenreich et al., 2003; Dunne et al. 2006) . Kasumi-1 cells were electroporated with a control siRNA (mock), with siRNA against AML1/ETO (siAGF1) or a mismatched siRNA control (siAGF6). AML1/ETO was effectively knocked down, as shown by western blot (Figure 1a ). LAT2 mRNA upregulation by 9.6 ± 3.8-fold (Po0.01) was detected by real-time quantitative PCR after two electroporations with the AML1/ETO-siRNA (Figure 1b ). This was confirmed by the appearance of a faint band in the lower range of sensitivity of a northern blot after a 14-day exposure of the membrane, but was below the detection level of a western blot (data not shown).
We next asked whether AML1/ETO directly binds to the LAT2 gene, using chromatin immunoprecipitation (ChIP) with an antibody directed against ETO. The gene regions interrogated by ChIP were: the transcription start site (TSS, amplicon 2), upstream gene region (1.5 kb 5 0 upstream of the TSS, amplicon 1) and LAT2 intron 3 (amplicons 3 and 4), where binding of RUNX1 was observed by ChIP sequencing (Martens and Stunnenberg, personal communication) (Figure 2a) . Interestingly, intron 3 sequences of LAT2 were significantly enriched after ChIP with the anti-ETO antibody in Kasumi-1 cells compared with U937 cells (Figure 2b , upper panel). As control for ChIP procedure, we chose the TBP (TATA box binding protein) gene, which is known to have no bona fide AML1 consensus binding sites (Lamprecht et al., 2010) . Indeed, no AML1/ETO occupancy was found as measured by real-time DNA-PCR after ChIP with anti-ETO antibody (Figure 2b , lower panel).
The LAT2 gene of AML1/ETO-expressing and nonexpressing cells is differentially marked by both activating and inactivating histone modifications We next hypothesized that the chromatin of the LAT2 gene is differentially marked depending on the expression (or absence thereof) of AML1/ETO. Several 'activating' (acetylated histones H3, H3K9, histone H4 and trimethylation of H3K4) and 'inactivating' histone marks (di-and trimethylation of histone H3K9, trimethylation of H3K27) were quantified by ChIP followed by quantitative PCR in the presence or absence of constitutively expressed AML1/ETO protein (comparison of U937 and Kasumi-1 cells). The transcription start site (amplicon 2) was strongly marked by acetylated H3, H3K9ac and H3K4me3 predominantly in U937 cells, in line with the model published by Barski et al. (2007) Figure 3a ). Somewhat unexpectedly, we found that for H3K9me2, the LAT2 gene was also marked in U937 expressor cells (less so in Kasumi-1 cells in which the LAT2 gene is silenced, Figure 3b ). H3K9me3 was enriched for amplicon 1 (that is, in the 5 0 -upstream region) in Kasumi-1 cells; similarly, the 'silencing' mark H3K27me3 was set in the intron-3 region of Kasumi-1 cells, and less so in U937 (ChIP experiments of the other two amplicons yielded unstable results with the antibody used, precluding firm conclusions regarding the marking of these other regions). In conclusion, the LAT2 gene is characterized by a reduction of activating histone marks and an increase of inactivating histone marks in potentially regulatory regions in AML1/ETO-expressing Kasumi-1 cells as compared with the AML1/ETOnegative cell line U937.
Repression of LAT2 is readily reversed by the HDAC class I-specific inhibitors entinostat and mocetinostat AML1/ETO-mediated gene repression can be antagonized by HDAC inhibitors (Klisovic et al., 2003; Claus et al., 2006) . We wished to identify optimal concentrations and time points at which an HDAC inhibitor derepressed LAT2 in AML1/ETO-positive cells. Therefore, a panel of different compounds was tested: 0 exon 1) and an intragenic region (intron 3, probed by amplicons 3 and 4). Arrows represent canonical AML1 binding sites (intron 3: 6/6 nucleotides, 5/6 nucleotides in the remaining regions). Alu sequence and exon 1 are indicated. (b) DNA binding of AML1/ETO (upper panel) was studied by ChIP using the anti-ETO antibody (Calbiochem) in Kasumi-1 and U937 cells, with normal rabbit IgG (NIgG) as non specific antibody. Immunoprecipitates (at least three independent experiments) were quantified by DNA quantitative PCR (qPCR) (primers listed in Materials and methods). As a negative control, DNA qPCRs of two regions of the TBP gene, known to have no AML1 binding sites on its promoter (Lamprecht et al., 2010) , were performed (lower panel). Student's t-test was applied to test for significance. NS, not statistically significant; *P ¼ 0.05. **Po0.01.
Kasumi-1 were treated for 24 h with increasing concentrations of the benzamides entinostat (MS-275, SDX-275) and mocetinostat (MGCD0103), the hydroxamates trichostatin A and suberoylanilide hydroxamic acid, and the aliphatic acids VPA and phenylbutyrate (PB). By western blot, LAT2 protein was strikingly induced by the two class I-specific compounds but not the other inhibitors at equitoxic concentrations ( Figure 4a and data not shown). LAT2 was induced in a dose-dependent manner by both entinostat and mocetinostat (Figures 4b and c), with induction first seen at 0.1 mM with either drug. To demonstrate successful HDAC inhibition, we also determined the global level of acetylation of histone H3 and H4, and showed the induction of p21 waf1 expression (Figures 4a, b and d) (Richon et al., 2000; Jiemjit et al., 2008) . We next compared entinostat and mocetinostat in a time course for up to 48 h. An overall similar induction of LAT2 was seen ( Figure 4d ), with entinostat inducing LAT2 maximally at 24 h, and expression remaining stable until 48 h. Mocetinostat induced LAT2 already after 12 h, with expression decreasing after 48 h.
To confirm the specificity of entinostat in reversing AML1/ETO-mediated LAT2 repression, we next treated another AML1/ETO-positive cell line (SKNO-1) and two AML1/ETO-negative cell lines (HL-60 and U937). LAT2 mRNA was re-expressed (14.3 ± 3.6-fold) in the AML1/ETO-positive cell line SKNO-1, but not in U937 (1.1±0.3-fold) and HL60 (0.9±0.3-fold) (Figure 4e ), supporting that entinostat induces LAT2 specifically in AML1/ETO-positive cells.
Entinostat induces both histone acetylation and histone methylation at the LAT2 transcription start site To address whether entinostat has a direct effect upon histone acetylation by inducing activating chromatin marks on the LAT2 gene, ChIP was performed. Indeed, treatment of Kasumi-1 cells with 1 mM entinostat for 24 h induced acetylation of histone H3 and H3K9 and, in addition, trimethylation of histone H3K4 at the LAT2 transcription start site. In contrast, only moderate acetylation of histone H4 was noted (Figure 5a ). Identical changes of these three histone marks were found on the transcription start site of p21 waf1 (Figure 5b ). The establishment of these activating histone marks was associated with a release of HDACs 1-3 from the LAT2 promoter (data not shown).
Effects of entinostat combined with decitabine upon LAT2 expression and histone acetylation The LAT2 promoter has a bona fide CpG island. Its methylation status was determined in Kasumi-1 cells by bisulfite sequencing of more than 10 alleles, and showed ChIP assays were performed with antibodies for 'inactivating' marks: dimethylation of histone H3 lysine 9 (H3K9me2), trimethylation of histone H3 lysine 9 (H3K9me3), trimethylation of H3 lysine 27 (H3K27me3). NIgG was used as non specific antibody, acetylation of histone H3 was used as positive control.
no methylation at its 12 CpG sites (Figure 6a ). When Kasumi-1 cells were treated for 72 h with concentrations of decitabine ranging from 25 to 200 nM, LAT2 expression was modestly increased in a dose-dependent manner, maximum 2.7-fold at 200 nM ( Figure 6b ). When Kasumi-1 cells were treated with 25 nM decitabine for 3 days, followed by entinostat (0.5 mM) for another 24 h, we noted an at least additive effect on the expression of LAT2 (Figure 7a ). This was accompanied by a global increase in histone H3 and H4 acetylation (Figure 7b ). Interestingly, decitabine alone (25 nM) also induced some histone acetylation, as previously described (Jiemjit et al., 2008) , and the combination of decitabine and entinostat markedly enhanced global acetylation of histones H3 and H4. At these concentrations, p21 waf1 expression was induced by 0.5 mM entinostat but not by 25 nM decitabine, and the combination had no additive effect on p21 waf1 expression (data not shown). Viability and cell proliferation were decreased by the combination of both compounds (Figures 7c and d) . A statistically significant interaction between decitabine and entinostat was shown regarding cell viability (P ¼ 0.005). waf1 , acetylation of histones H3 and H4 were studied by western blot. Anti-b-actin antibody was used as loading control. (e) LAT2 mRNA was studied in AML1/ETO-positive SKNO-1 and in AML1/ETO-negative U937 and HL-60 cell lines before and after treatment with entinostat. Cells were treated with entinostat for 24 h and LAT2 mRNA expression was measured by real-time qPCR. b-Glucuronidase (GUSB) was used to normalize expression levels. Bars indicate mean and error bars indicate s.d. of at least three independent experiments.
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Discussion
Epigenetic gene silencing events are increasingly recognized as early steps during the initiation of leukemogenesis, in addition to propagating gene silencing during progression of leukemia (Lu¨bbert, 2003; Fazi et al., 2005) . Oncofusion proteins resulting from recurrent balanced chromosomal translocations in AML offer valuable model systems to investigate the epigenetic alterations induced at target genes of these aberrant transcription factors. The PML/RARa fusion protein has been demonstrated to recruit not only HDACs but also DNMT activity to its target genes, such as RARb2, thereby rendering this gene in a silenced state through promoter hypermethylation and by imposing an inactive chromatin structure (Di Croce et al., 2002; Fazi et al., 2007) . Several MLL (mixed-lineage leukemia) fusion proteins have also been extensively characterized as recruiters of chromatin-modifying enzymes (Krivtsov and Armstrong, 2007) . Furthermore, the AML-specific fusion protein AML1/ETO recruits HDAC activity to target genes, and is under investigation as a protein rendering the CpG islands of its target genes hypermethylated through DNMT recruitment (Liu et al., 2005; Fazi et al., 2007) . A better understanding of oncofusion proteins as mediators of epigenetically silenced states also drives the search for 'targeted' therapies that specifically antagonize their repressive effects. Examples for clinical models include treatment of PML/RARa transgenic mice with HDAC inhibitors, as well as AML1/ETOexpressing cell lines and transgenic cell models (Yang et al., 2007; Barbetti et al., 2008) . Recently, the group of Clara Nervi has shown that the hypermethylated state of the RARb2 promoter CpG island can be converted to a demethylated, transcriptionally active promoter by treatment with the DNA-demethylating agent 5-azacytidine (Fazi et al., 2007) . LAT2 has been characterized as an adaptor molecule involved in the activation of mast cells as well in signalling through the B-cell receptor. We previously characterized LAT2 as a target gene of AML1/ETO, . We now show that AML1/ETO binds to intron-3 sequences of the LAT2 gene. We hypothesize that this intronic region may have a regulatory function, for example, as an enhancer. The recruitment of AML1/ETO to the intron 3 of the LAT2 gene results in a decrease of activating histone marks in all studied regions and modification of inactivating histone marks. The inactivating histone mark H3K9me3 was enriched in a region ca 1.5 kb upstream of the TSS of LAT2. Interestingly, the polycomb mark H3K27me3 was enriched in intron 3 of LAT2. Conversely, a knockdown of AML1/ETO resulted in a partial relief of this transcriptional repression, further supporting the role of LAT2 as a target gene of AML1/ETO. In order to antagonize the epigenetic repressor function of AML1/ETO on its in vivo target gene, we treated the Kasumi-1 cells with several HDAC inhibitors, including the hydroxymate derivates suberoylanilide hydroxamic acid and Trichostatin A, the small chain fatty acids VPA and PB, and the benzamides entinostat (formerly MS-275) and mocetinostat (formerly MGCD0103). We now show that both the HDAC class I-specific inhibitors entinostat (clinically developed for treatment of myeloid and other malignancies, both as single agent and in combination with 5-azacytidine) and mocetinostat (studied in phase I/II clinical trials of hematological malignancies and solid tumors) are very effective in relieving the transcriptional repression imposed on the LAT2 promoter by AML1/ETO, with robust LAT2 induction on the protein level. Khan et al. (2008) have shown that entinostat and mocetinostat are very potent class I-specific HDACs inhibitors, especially against HDAC 1 and 2. Of note, the maximal induction of LAT2 by entinostat was reached after 24 h and remained for at least 48 h, but the induction by mocetinostat was maximal after 12 h and decreased after 48 h. This effect correlates with clinical parameters: entinostat is more stable (half-life between 39 to 80 h) than mocetinostat (half-life 9 h) (reviewed by Tan et al., 2010) . The higher potency of entinostat was only specific for LAT2 as shown in a drug comparison with several HDAC inhibitors inducing similar p21 waf1 protein expression and in AML1/ETO-expressing cells (Figure 4) .
As determined by chromatin immunoprecipitation assays, entinostat induced several activating chromatin marks at the LAT2 transcription start site. Interestingly, entinostat also had an effect upon trimethylation of H3K4. Other HDAC inhibitors like PB, VPA (Nightingale et al., 2007) and trichostatin A (Paul et al., 2010) have been described to induce trimethylation of H3K4, suggesting a functional link between histone acetylation and histone methylation. The group of Constanze Bonifer described the interaction between AML1 (RUNX1) and the initiation of chromatin remodeling through trimethylation of H3K4 in pluripotent hematopoietic precursors cells, suggesting that Epigenetic regulation of LAT2 by AML1/ETO J Duque-Afonso et al the epigenetic changes of AML1/ETO target promoters may be due to modification not only in histone acetylation but also in histone methylation (Hoogenkamp et al., 2009) . Others (Peterson et al., 2007 , Viale et al., 2009 as well as ourselves (Berg et al., 2008) have described that p21 waf1 expression is induced by AML1/ETO. In this study, p21 waf1 protein expression was confirmed in Kasumi-1 cells (Figure 4 ). We now demonstrate that the induction of p21 waf1 by AML1/ETO is enhanced by HDAC inhibitors, indicating that this effect is not antagonized by HDAC inhibition. As expected from results generated in other contexts (Richon et al., 2000) , HDAC inhibitors strongly increase p21 waf1 expression in Kasumi-1 (which is relatively low at baseline even in the presence of AML1/ETO). Therefore, the regulation of p21 waf1 through HDACs is dominant over the effect of AML1/ETO. LAT2 epigenetic silencing in AML1/ETO-positive leukemia does not appear to be mediated by promoter hypermethylation, as this gene has only a weak CpG island, which we found to be unmethylated in Kasumi-1 cells. In line with this result, treatment of these cells with the hypomethylating agent decitabine did not result in significant upregulation, and the marked induction by entinostat could not be synergistically enhanced by pretreatment with a DNA-demethylating agent.
Interestingly, we found that decitabine influenced the acetylation status of both histone H3 and H4. Cameron et al. (1999) first reported the synergistic effect of DNMT inhibitors with HDAC inhibitors on global acetylation of histones H3 and H4. This was also detected in vivo in peripheral blood leukocytes from AML/MDS patients undergoing treatment with the DNMT inhibitor 5-azacytidine and the HDAC inhibitor sodium PB (Gore et al., 2006; Maslak et al., 2006) , and with decitabine and VPA (Garcia-Manero et al., 2006; Blum et al., 2007) .
In conclusion, we could show that LAT2, as a direct target gene of AML1/ETO, is repressed by epigenetic mechanisms imposed by the oncofusion protein, and antagonization by a class-I specific HDAC inhibitor reverted these epigenetic silencing marks. Clinical trials are ongoing that investigate the role of HDAC inhibitors in patients with AML1/ETO-positive AML.
Materials and methods
Cell lines, cell culture and drugs Kasumi-1, U937 and HL-60 cells were purchased from the DSMZ (GmbH, Braunschweig, Germany) and SKNO-1 was kindly provided by SD Nimer (Division of Hematologic Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA). Cells were cultured in RPMI 1640 medium (PAA Laboratories, Co¨lbe, Germany) supplemented with 100 U/ml penicillin/streptomycin and 10% fetal calf serum (PAA laboratories), except Kasumi-1 cells with 20% fetal calf serum, at 37 1C and 5% CO 2 . SKNO-1 cells (10% fetal calf serum) were supplemented with 10 ng/ml granulocytemacrophage colony stimulating factor (GM-CSF) (CellGenix, Freiburg, Germany). The AML1/ETO-inducible U937 cells (9/14/18) were described elsewhere (Fliegauf et al., 2004) . AML1/ETO expression was induced with 5 mM Ponasterone A (Invitrogen, Carlsbad, CA, USA).
Electroporation of Kasumi-1 cells with siRNAs was performed as described (Heidenreich et al., 2003; Dunne et al., 2006) . Kasumi-1 cells were treated with different concentrations of HDAC inhibitors for 24 h: trichostatin A (Sigma, Taufkirchen, Germany) dissolved in ethanol; suberoylanilide hydroxamic acid (Alexis Biochemicals, San Diego, CA, USA) dissolved in methanol; entinostat (MS-275, SDX-275; kindly provided by Schering AG, now Bayer Schering Pharma, Berlin, Germany) dissolved in dimethyl sulfoxide; mocetinostat (MGCD0103, Selleck Chemicals, Houston, TX, USA) dissolved in dimethyl sulfoxide, valproic acid and phenylbutyrate (Sigma) dissolved in water. U937, HL60 and SKNO-1 cells were treated with 1 mM entinostat for 24 h. Kasumi-1 cells were also treated with the DNMT inhibitor 5-aza-2 0 -deoxycytidine (Decitabine, DAC, Sigma), dissolved in phosphate-buffered saline, with pulses every 24 h for 3 days and concentrations ranging from 25 to 200 nM.
RNA isolation and reverse transcriptase reaction RNA was isolated using the RNeasy Kit (Qiagen, Hilden, Germany). For quantification studies by real-time reverse transcriptase-PCR, complementary DNA was generated from isolated RNA using the SuperScript Reverse Transcriptase II (Invitrogen), following the manufacturer's recommendations.
Protein isolation
Proteins were isolated with a modified RIPA lysis buffer containing 50 mM Tris-HCl, 1% NP-40, 1% laurylmaltoside, 150 mM NaCl, 1 mM EDTA, 1 mM phenylmethylsulphonyl fluoride, 1 mM Na 3 VO 4 and 1 mM NaF. Protein concentration was determined by Bradford assay (BioRad, Mu¨nchen, Germany).
Western blot
Equal amounts of proteins were separated using 12% Bis/Tris gels in a NuPAGE electrophoresis system (Invitrogen). Proteins were transferred to Hybond-P membrane (GE Healthcare, Uppsala, Sweden). Antibodies used for immunodetection were mouse anti-NTAL/LAT2 (ExBio, Praha, Czech Republic), rabbit anti-acetyl histone H3, rabbit anti-acetyl histone H4 and mouse anti-b-actin (Sigma), anti-ETO (Calbiochem, Nottingham, UK) and anti-p21 waf1 (Santa Cruz Biotechnology, Delaware, CA, USA). Bands were detected by chemiluminescence using ECL Plus Western blotting Detection System and HyperFilm (Amersham).
Chromatin immunoprecipitation
The protocol to perform chromatin immunoprecipitation was modified from Hauswald et al. (2009) . Lysates were incubated overnight in ChIP dilution buffer with the primary antibodies anti-acetyl histone H3 (AcH3), anti-acetyl histone H4 (AcH4), anti-acetyl histone H3 lysine 9 (H3K9ac), anti-trimethyl histone H3 lysine 4 (H3K4me3), anti-dimethyl histone H3 lysine 9 (H3K9me2), anti-trimethyl histone H3 lysine 9 (H3K9me3) and anti-trimethyl histone H3 lysine 27 (H3K27me3), all purchased from Upstate (Lake Placid, NY, USA); anti-ETO (Calbiochem, Gibbstown, NJ, USA) and normal rabbit antibody (Santa Cruz Biotechnology) as control antibody. Precipitates were washed once with ChIP dilution buffer, TSE I, TSE II, LiCl buffer and twice with TE Buffer. Desorption was performed in 1% SDS and 0.1 M NaHCO 3 solution and crosslinking was reversed by incubation of the samples at 65 1C for 4-6 h or overnight. DNA was isolated using the PCR purification kit (Qiagen).
Real-time quantitative PCR
Quantification of expression of AML1/ETO, LAT2 and p21 waf1 was performed in a Light Cycler 480 based on SYBR Green I technology (Roche, Mannheim, Germany) with standard conditions. The samples were standardized to the expression of the housekeeping genes glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and b-Glucuronidase (GUSB). All samples were measured in duplicates and expression was quantified by the method of absolute quantification/second derivative maximum after comparison with a standard curve. The following primers were used:
GUSB forward primer 5 0 -CGCCCTGCCTATCTGTATTC -3 0 , GUSB reverse primer 5 0 -TCCCCACAGGGAGTGTGTAG -3 0 Quantification of DNA after ChIP assay was performed as described above, standardized to 5% input. The following primers were used: LAT2-5 0 (amplicon 1) forward primer 5 0 -CAGACATGAG GACCGAGTGA-3 Bisulfite sequencing Bisulfite sequencing was described elsewhere (Berg et al., 2007) . Genomic DNA was first isolated with the DNeasy Tissue Kit (Qiagen). The bisulfite conversion was performed using the EZ DNA Methylation Kit (Zymo Research, Irvine, CA, USA) following the recommendations of the manufacturer. The DNA was amplified by PCR using standard conditions, and finally the PCR products were subcloned in the pCR2.1-TOPO Vector (Invitrogen) and competent bacteria were transformed (E. coli OneShot Mach1 tm T1R Chemically Competent, Invitrogen). The plasmids were sequenced by GATC (Konstanz, Deutschland).
Statistics
Statistical analysis of data was performed using the SPSS v16.0 software (SPSS Inc., IBM, Chicago, IL, USA) with analysis of variance, Student's t-test to test differences between groups and regression linear model for drug's interaction.
